Mark Lebwohl, MD, delivered a highly anticipated, high-yield presentation packed with clinical pearls and cutting-edge data. He began by highlighting new data on emerging treatments for basal cell carcinoma, including research on the use of L-carnitine to reduce muscle cramps in patients taking vismodegib. Dr Lebwohl then transitioned to psoriasis, discussing new guidelines from the Medical Board of the National Psoriasis Foundation. These guidelines offer crucial direction for clinicians on whether to pause specific systemic immunomodulatory therapies in patients with psoriasis and psoriatic arthritis undergoing procedures. He went on to cover other essential regulatory updates related to the increasing use of immunomodulatory agents in dermatology, including the important issue of live vaccine administration in these patients. On the topic of vaccinations, Dr Lebwohl delved into timely discussions around herpes zoster vaccination, the elevated risk of herpes zoster among older patients with immune-mediated diseases, COVID-19 vaccination considerations in patients with psoriasis, and broader vaccination recommendations for adults receiving biologic and oral therapies for psoriasis.